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dbstract
UN1 is a membrane glycoprotein that is expressed in immature human thymocytes, a subpopulation of peripheral T lymphocytes, the HPB acute
ymphoblastic leukemia (ALL) T-cell line and fetal thymus. We previously reported the isolation of a monoclonal antibody (UN1 mAb) recognizing
he UN1 protein that was classified as “unclustered” at the 5th and 6th International Workshop and Conference on Human Leukocyte Differentiation
ntigens. UN1 was highly expressed in breast cancer tissues and was undetected in non-proliferative lesions and in normal breast tissues, indicating
role for UN1 in the development of a tumorigenic phenotype of breast cancer cells. In this study, we report a partial purification of the UN1
rotein from HPB-ALL T cells by anion-exchange chromatography followed by immunoprecipitation with the UN1 mAb and MALDI-TOF MS
nalysis. This analysis should assist in identifying the amino acid sequence of UN1.
2006 Elsevier B.V. All rights reserved.
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. Introduction
The murine monoclonal antibody (mAb) UN1 was previ-
usly selected for the specific reactivity with human thymocytes
s compared to peripheral blood cells [1]. The antigen recog-
ised by UN1 mAb is a 100–120 kDa transmembrane glycopro-
ein showing biochemical features of cell membrane-associated
ucin-like glycoproteins, a class of macromolecules that are
nvolved in cell-to-cell interactions and cancer progression [2,3].
he UN1 protein was expressed at high levels on the majority
f human thymocytes and a small subpopulation of peripheral
lood T lymphocytes [1,3]. UN1 was also expressed on the cell
embrane of leukemic T-cell line and solid tumors [4]. UN1
 This paper was presented at the Challenging Proteins Workshop in Paris,
ctober 17–18, 2005.
∗ Corresponding author. Tel.: +39 961 3694057; fax: +39 961 3694090.
E-mail address: annadela@unicz.it (A. de Laurentiis).
expression was investigated on normal and pathological breast
tissues by immunohistochemical and Western blotting analy-
sis [5]. The protein was absent in normal breast and benign
non-proliferative lesions, moderately expressed in the majority
of tested fibroadenomas, and highly expressed in proliferative
lesions, both in situ or infiltrating carcinomas. In particular,
metastatic lesions showed the highest levels of UN1 [5]. These
results underscore a direct correlation between the expression of
UN1 and the development of a tumorigenic phenotype of breast
tissue. In this regard, UN1 may function as a specific marker of
breast cancer.
This study is aimed at the identification of the amino acid
sequence of the UN1 protein; to this end, total proteins extracted
from HPB-ALL T cells were subjected to anion-exchange chro-
matography followed by immunoprecipitation with UN1 mAb.
The UN1 immunocomplex was fractionated on SDS-PAGE and
stained with coomassie blue. The protein band corresponding to
UN1 was in situ digested with trypsin. Tryptic fragments were
analysed by matrix-assisted laser desorption ionization-time of
141-8130/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
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flight mass spectrometry (MALDI-TOF MS). In addition, we
also report a strategy to optimize the purity of the sample for the
mass spectrometry analysis by coupling the UN1 mAb-mediated
immunoprecipitation with a mimotope-based displacement of
the UN1 protein.
2. Experimental procedures
2.1. Monoclonal antibody
The UN1 mAb was produced by the hybridoma technology
and selected on the basis of its high reactivity with human imma-
ture thymocytes, as previously described [1]. UN1 mAb was
collected as hybridoma supernatant or ascites and purified by
affinity chromatography on protein A-Sepharose (Amersham
Biosciences, Uppsala, Sweden) [6].
2.2. Protein extract
HPB-ALL cells (8 × 109) were resuspended in Phosphate
Buffered Saline (PBS) lysis buffer containing the Protease
Inhibitor Cocktail CompleteTM (Roche, Mannheim, Germany)
and 1% Triton X-100 (Sigma, St. Louis, USA). The suspension
was placed on ice for 30 min, occasionally mixed, and subjected
to three cycles of freezing and thawing. The cell lysate was cen-
trifuged at 15,000 × g for 30 min at 4 ◦C and the supernatant
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Fig. 1. DEAE-Sepharose Fast Flow chromatography. (a) The total cell-
free extract of HPB-ALL was applied on a DEAE-Sepharose column
(1.6 cm × 10 cm) equilibrated and eluted as reported in the experimental sec-
tion. About 10 ml fractions were collected at a flow rate of 2 ml/min. (b) The
cell extract (30g, first lane), flow through (20l, second lane) and eluted frac-
tions (20l, following lanes) were separated on 8% SDS-PAGE and analysed
by Western blotting using the UN1 mAb.
280 nm. Fractions of 10 ml were collected and analysed for the
presence of UN1 by Western blotting (Fig. 1a and b). The pos-
itive fractions were pooled together and dialysed against buffer
A. The sample (70.3 mg proteins) was then applied to a MonoQ
HR 10/10 column (Amersham Biosciences) and equilibrated at
1 ml/min with buffer A. The bound proteins were eluted with
30 ml of a 0–500 mM NaCl gradient in buffer A. Fractions of
1 ml were collected and tested for UN1 by Western blotting. Pos-
itive fractions were pooled together and dialysed against PBS
buffer containing 0.1% Triton X-100, and concentrated by dial-
ysis against PBS buffer, 0.1% Triton X-100, 50% glycerol.
2.5. Immunoprecipitation
The MonoQ purified sample was ultrafiltrated by Amicon
membrane (cutoff > 30 kDa), adjusted to 0.5% Triton X-100 and
precleared by incubation with 4g of normal mouse IgG (Santa
Cruz Biotechnology, CA, USA) coupled to 30l of Protein G
beads (Amersham Biosciences) in a rotating agitator for 2 h at
4 ◦C. Following centrifugation at 800 × g, the supernatant was
incubated with 4g of UN1 mAb bound to 30l of Protein G
beads for 16 h in a rotating agitator at 4 ◦C. The immunocom-
plex was recovered by centrifugation and the pellet was washed
extensively with PBS, 1% Triton X-100.
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f46 ml, 12.2 mg/ml) was recovered for further purification.
.3. Western blotting and immune detection
The proteins were separated by 8% SDS-PAGE according to
he Laemmli method [7] and electroblotted into nitrocellulose
embranes at 20 V for 16 h in 150 mM glycine–20 mM Tris.
he membrane was pre-incubated with 5% blocking reagent
BioRad, Hercules, CA, USA) in PBS and then incubated with
N1 mAb (2g/ml) in PBS containing 5% blocking reagent
or 2 h at room temperature, followed by incubation with sheep
nti-mouse IgG horseradish peroxidase conjugated (Amersham
iosciences) in PBS in presence of 5% blocking reagent for
h at room temperature. The strips were washed, treated with
CL Western blotting kit (Amersham Biosciences) and exposed
o X-ray film (Amersham Biosciences). To quantify the UN1
rotein, the film was analysed by scanning densitometry and
he specific signal was evaluated as number of pixels/g of
rotein.
.4. Chromatographic techniques
Anion exchange chromatography was performed on columns
onnected to a FPLC system (Amersham Biosciences). In par-
icular, a DEAE-Sepharose Fast Flow (Amersham Biosciences)
olumn (1.6 cm × 10 cm) was equilibrated in 20 mM Tris/HCl,
H 7.8 containing 0.1% Triton X-100 (buffer A) at a flow rate
f 2 ml/min. The total protein extract (560 mg) was applied to
he column, which was washed with buffer A; bound proteins
ere eluted with 300 ml of a 0–500 mM NaCl linear gradient in
uffer A. The elution profile was monitored by absorbance at.6. Mimotope-based displacement
The peptide 16-4, which mimics the antigenic epitope of
N1 mAb, was used to elute the UN1 protein from the
mmunocomplex. The 16-4 mimotope was previously selected
y screening a random peptide library displayed on filamentous
d phages using the UN1 mAb [8]. To select the conditions for
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the release of UN1 from the immunocomplex, the HPB-ALL cell
extract (400g) was immunoprecipitated with UN1 mAb (2g)
bound to Protein G beads (20l); then, the immunocomplex was
incubated with increasing amounts of 16-4 peptide (0.26, 1.3 or
2.6 mM) in 100l of PBS, 0.5% Triton X-100 for 16 h at 4 ◦C.
The UN1 protein was recovered by centrifugation at 800 × g
for 1 min at 4 ◦C; supernatant and pellets were analysed for the
UN1 presence by Western blotting and quantified by scanning
densitometry.
2.7. Colloidal coomassie blue staining
The colloidal coomassie blue staining was prepared by resus-
pending 0.15% (w/v) Coomassie Brilliant Blue G-250 (BioRad)
in 2% (v/v) phosphoric acid and 10% (w/v) ammonium sulphate.
After electrophoresis, the gels were fixed in 40% methanol,
10% acetic acid for 1 h and proteins were stained with col-
loidal coomassie blue containing 20% methanol for 36 h, and
destained in water; the limit of protein detection by this method
is 10–15 ng.
2.8. In situ digestion
Protein bands were excised from the gel, cut in pieces and
washed with acetonitrile and with 0.1 M ammonium bicarbon-
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2.10. Database searching
MALDI raw data were inserted into the web-available search
program Mascot (http://www.matrixscience.com) to search for
non-redundant protein sequence database (NCBInr) by taking
advantage of the specificity of the proteolytic enzyme used for
the hydrolysis and the taxonomic category of the sample. Pro-
teins were identified by selecting the following item:Homo sapi-
ens as taxonomic category; trypsin as enzyme; up to two missed
cleavages; cysteines as S-carbamidomethylcysteines; unmodi-
fied N- and C-terminal ends; methionines both as unmodified
and as oxidised. Only experimental values within 0.03% accu-
racy were recorded. Three independent sets of experiments were
performed.
2.11. Construction of p3xFLAG-CMV-ELKS-α and
transfection of HeLa cells
The sequence of ELKS- cDNA was amplified by PCR from
pDR2ELKS- with the primers 5′-GGA ATT CCA TGT ATG
GAA GTG CCC GCT C and 3′-TCC CCC GGG CTA TGC
CCA TAT ACC CTC CTC. The PCR product was ligated to
p3xFLAG-CMV 7.1 (Sigma) after digestion with EcoRI and
SmaI, to generate p3xFLAG-CMV-ELKS-. HeLa cells were
transfected with 10g of p3xFLAG-CMV-ELKS- using Cal-
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Mte. Protein samples were treated with 10 mM DTT for 45 min at
6 ◦C and alkylated with 55 mM iodoacetamide in 0.1 M ammo-
ium bicarbonate for 30 min at room temperature in the dark,
s previously described [9]. Enzymatic digestions were carried
ut with modified trypsin (Roche) (12.5 ng/l) in 50 mM ammo-
ium bicarbonate, pH 8.5, at 4 ◦C for 45 min and then incubated
t 37 ◦C for 18 h. Peptides were extracted by washing the gel
ith acetonitrile and lyophilised.
.9. Peptide mapping
MALDI spectra were recorded using a reflectron Voyager
E PRO MALDI-TOF mass spectrometer (Applied Biosys-
ems, Norwalk, CT, USA). An aliquot of the peptide mixture
1l) was added to 1l of MALDI matrix solution [-cyano-4-
ydroxycinnamic acid (Sigma) 10 mg/ml in acetonitrile: 0.2%
FA = 7:3 (v/v)] and then spotted onto a stainless steel sample
late and allowed to dry. Spectra were acquired in a reflectron
ode; the mass range was calibrated using the MH+ ions from
he standard peptide mixture provided by the manufacturers.
aw data were analysed using computer software provided by
he manufacturers.
able 1
urification steps of UN1
tep Total protein (mg) Total activity (pixel)
ell extract 562.1 432740
EAE 70.3 325677
onoQ 11.8 76960ium Phosphate Transfection kit (Invitrogen, Carlsbad, CA,
SA) and total protein extract was analysed for the expres-
ion of ELKS- by Western blotting with anti-FLAG M2 mAb
Sigma).
.12. Protein assay
The concentration of proteins was determined by the method
f Bradford [10] using human serum albumin as standard.
. Results
The HPB-ALL T cells expressing high levels of the UN1 pro-
ein were used as source for the purification of UN1. Total protein
xtract was separated by anion-exchange chromatography using
EAE and MonoQ columns. UN1 was undetected in the flow
hrough fraction of both columns and eluted with NaCl gradient
Fig. 1a). Table 1 summarizes the purification procedure giving
18% final yield with a purification factor of 8.4. The MonoQ
urified sample was immunoprecipitated with the UN1 mAb.
he UN1 immunocomplex was separated on SDS-PAGE and
tained with coomassie blue; as control, a small fraction of the
mmunoprecipitated sample was separated on the same gel and
Specific activity (pixel/mg) Purification factor Yield (%)
769.9 1 100
4632.7 6.0 75
6522.0 8.5 18
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Table 2
Description of the putative candidate ELKS-
Name ELKS isoform alpha [Homo sapiens]
NCBI (accession no.) 14149661
MW (Da) 108840
MASCOT score 86
Sequence coverage 7%
Number of identified peptides 7
transferred to nylon membrane for Western blotting analysis.
UN1 was detected as a 100–120 kDa protein band by Western
blotting analysis and undetected by coomassie staining. Next,
a band was excised from the gel at the size level of UN1 as
detected by Western blotting, and in situ digested with trypsin.
The eluted peptides were extracted from the gel for further anal-
ysis by MALDI-TOF MS. Maldi spectra were characterised by
the presence of several mass signals originated by contaminant
keratins. Few signals could be selected for protein identification
and used within Mascot software to screen a non-redundant pro-
tein data bank. The results led to the identification of ELKS-
[11] as a putative candidate protein with a molecular mass of
about 110 kDa (Tables 2 and 3). The identification score was
just above the statistical limit thus making necessary a valida-
tion of the identification with an independent procedure. In order
to verify the candidate gene, the cDNA coding ELKS- was
cloned into the p3xFLAG-CMV eukaryotic expression vector
and transiently transfected in HeLa cells. The total extracts from
transfected and untransfected cells were analysed by Western
blotting using the UN1 mAb and anti-FLAG mAb. The results
indicated that UN1 did not correspond to ELKS-, as the UN1
mAb did not detect the ELKS- transfected protein (Fig. 2, lanes
1 and 3).
In order to improve the purity of UN1 for the mass spectrom-
etry, the 16-4 peptide mimicking the UN1 epitope recognised
by the UN1 mAb was used to remove UN1 from the immuno-
c
w
b
a
m
p
T
I
P
Q
A
Q
S
A
E
D
Fig. 2. The UN1 mAb does not recognize the ELKS- protein. Total extracts
(30g) of HPB-ALL (lane 5) and HeLa cells transfected with p3xFLAG-CMV-
ELKS- (lanes 1, 3) or untransfected (lanes 2, 4) were analysed by Western
blotting using the UN1 mAb or anti-FLAG mAb.
Fig. 3. The 16-4 peptide displaces UN1 from the immunocomplex. (a) The UN1
mAb–UN1 antigen complex was incubated with the indicated 16-4 peptide/UN1
mAb molar ratio. After centrifugation, the supernatant (S) and the pellet (P) were
analysed by Western blotting with the UN1 mAb. (b) The displaced (empty bar)
and undisplaced (filled bar) UN1, shown in (a), were quantified by scanning
densitometry analysis.
method to allow a liquid proteolytic digestion of UN1 followed
by Liquid Chromatography/Mass Spectrometry (LC/MS).
4. Discussion
The UN1 mAb detects a membrane glycoprotein with an
apparent weight of 100–120 kDa. This antigen appears to be
expressed in early stages of T-cell ontogeny (immature thymo-
cytes) [4], a small subpopulation of peripheral blood T lympho-
cytes, leukemic T-cell line and solid tumors. This paper describes
the purification of UN1 protein from HPB-ALL cells using the
combination of DEAE, MonoQ ion-exchange chromatography
and immunoprecipitation with the UN1 mAb. The immunopre-
cipitated UN1 was not detected by coomassie blue staining of
the gel after SDS-PAGE; this suggests that the amount of puri-
fied UN1 was lower then 15 ng, which is considered the limit of
protein detection using the Colloidale Coomassie Blue staining.omplex. To this end, the UN1 immunocomplex was incubated
ith three dilutions of the 16-4 peptide overnight at 4 ◦C. The
ound (pellet) and the unbound (supernatant) UN1 protein were
nalysed by Western blotting (Fig. 3a). At the 5000-fold peptide
olar concentration, UN1 was displaced from the immunocom-
lex with a yield of about 75% (Fig. 3b). We plan to scale up this
able 3
dentified peptides by MALDI-TOF MS
eptide sequence Position along
ELKS isoform
alpha sequence
m/z Note
ELESMK 818–824 847.42 Pyro-glu(N –
termQ)
HEAALEAR 692–700 967.45
VKDQNKK 761–768 970.45 Pyro-glu(N –
termQ)
TMTLGRSGGR 87–97 1122.52
TEEDHERTR 325–334 1243.61
THLTNLRAER 838–848 1339.61
RLVQQLKQQTQNR 898–911 1754.96
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The MALDI-TOF analysis of the tryptic peptides obtained
by in situ digestion of the gel band corresponding to UN1 protein
as detected by Western blotting did not provide the identity of
UN1 protein. This was probably due to the low amount of puri-
fied protein and/or low efficiency elution of UN1 peptides from
the gel. Indeed, the size, hydrophobicity, and glycosylation of
UN1 could represent an obstacle to the in situ digestion of UN1
on gel. High-sequence coverage is difficult to obtain because the
membrane-spanning segments are either not readily accessible
to proteolytic enzymes, or lack the specific proteolytic cleavage
sites [12,13]. To overcome these hurdles, we are now attempt-
ing to purify UN1 from the immunocomplex by using the 16-4
peptide, a mimotope of UN1 antigen. Competition experiments,
ELISA and cytofluorimetric analysis have shown that the 16-
4 peptide efficiently displaced UN1 from the binding to UN1
mAb. The displaced UN1 will be further analysed by in liquid
proteolytic digestion and LC/MS.
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